Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974725 · ClinicalTrials.gov registry record · Phase 1
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 241
- Enrollment target
NCT02974725: Clinical Trial Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT02974725 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 241 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (302% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02974725, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 241 participants
- Enrollment target
Study Summary
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
Interventions
- DRUG Ribociclib
- DRUG Trametinib
- DRUG LXH254
- DRUG LTT462
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 1 |
Why NCT02974725 stopped before completion
NCT02974725 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (302% higher).
The record links to 0 conditions, and to 4 interventions - of which Ribociclib is the first listed.
NCT02974725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02974725 about?
NCT02974725 is a clinical study titled "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma". To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
What is the current status of trial NCT02974725?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 241 participants. The study started on 2017-02-24. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT02974725?
The interventions under investigation include: Ribociclib (DRUG), Trametinib (DRUG), LXH254 (DRUG), LTT462 (DRUG).
Who is sponsoring clinical trial NCT02974725?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02974725's enrollment target sits among peer trials
241 196th of 2000 higher than 1,804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT07213791 · 241 participants · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI